Tuesday, Oct 8, 2024 · SEC filings
What the smart money revealed on Oct 8
287 insider filings came in. We hid 68 planned (10b5-1) sellers and 177 people whose filings were routine, like grants and tax withholding.
Angiodynamics (ANGO) President and CEO James Clemmer bought $121K
20,000 shares on the open market. Not a grant or an option exercise. Their past buys: 2 of 3 checked quarters beat the typical stock 6 months later.
MoonLake Immunotherapeutics (MLTX) Director Simon Sturge sold $9.19M
Not marked as a planned 10b5-1 sale. Sold 50% of the shares they held directly. Still holds 171,980 shares.
Paychex (PAYX) Sr. Vice President Michael Gioja sold $2.05M
Not marked as a planned 10b5-1 sale. Most of the shares sold came from stock options they exercised the same day. Still holds 14,515 shares directly.
X4 Pharmaceuticals (XFOR) CFO Adam Mostafa sold $127K
Not marked as a planned 10b5-1 sale. Sold every share held directly.
Show 6 more real buys
Show 15 more real sales
13F season
Holdings as of Sep 30, 2024 are due Nov 14
58 funds have filed so far. 54 filed for the quarter before.
Biggest real insider buys, Oct 2–8
Open-market buys by officers and directors, filed in the 7 days up to Oct 8.
Free weekly email
Each week's biggest real insider buys, cluster buys and fund moves, every one dated. One email a week. Unsubscribe in one click.